Current and emerging therapies for hand eczema
- 28 January 2019
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (3) , e12840
Abstract
Purpose Though hand eczema (HE) and chronic hand eczema (CHE) are common conditions with significant disease burden, they traditionally have had limited treatment options beyond topical and short‐term systemic corticosteroids. We reviewed published and preliminary evidence on the current and emerging topical and systemic therapeutic agents for HE and CHE. The etiologies of various HE subtypes are discussed, and remaining knowledge and practice gaps are highlighted to encourage further investigations. Material and Methods A comprehensive search of ClinicalTrials.gov and PubMed was completed for clinical trials that utilized known and emerging treatment options for HE and CHE. Results Several agents that target IL‐4 and IL‐13 signaling, keratinocyte proliferation, inflammatory cytokine production, bacterial protein synthesis, and inflammatory mediator (TNF‐ α, JAK1, JAK2, JAK3) proliferation are shown to be involved in the pathogenesis of CHE. Systemic agents include dupilumab, alitretinoin, acitretin, cyclosporine, azathioprine, and probiotics. Topical agents include delgocitinib, retapamulin, halometasone/triclosan, calcipotriol/betamethasone, tacrolimus, and pimecrolimus. These modalities have demonstrated varying degrees of clinical efficacy, evaluated by subjective assessments and scoring indexes. Conclusions Targeted therapies are emerging for HE, but options are still limited, partially due to our narrow understanding of this heterogeneous condition. Additional and targeted therapeutic options are needed to match the rising prevalence and burden of HE.Keywords
This publication has 96 references indexed in Scilit:
- The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitisJAK-STAT, 2013
- Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspectsCellular and Molecular Life Sciences, 2011
- Atopic dermatitis: a disease of altered skin barrier and immune dysregulationImmunological Reviews, 2011
- The skin microbiomeNature Reviews Microbiology, 2011
- Tight junction defects in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2011
- Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6Clinical Immunology, 2008
- Retapamulin Inhibition of Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureus CellsAntimicrobial Agents and Chemotherapy, 2007
- Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial RibosomesAntimicrobial Agents and Chemotherapy, 2006
- Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitisNature Genetics, 2006
- Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.Journal of Clinical Investigation, 1994